444 related articles for article (PubMed ID: 34215690)
1. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
[TBL] [Abstract][Full Text] [Related]
2. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody.
Khalifa AM; Nakamura T; Sato Y; Sato T; Hyodo M; Hayakawa Y; Harashima H
Int J Pharm; 2022 Aug; 624():122034. PubMed ID: 35863595
[TBL] [Abstract][Full Text] [Related]
3. Cancer Immunotherapy with Lipid Nanoparticles Loaded with a Stimulator of Interferon Genes Agonist against Renal Tumor Lung Metastasis.
Nakamura T; Sasaki S; Sato Y; Harashima H
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258042
[TBL] [Abstract][Full Text] [Related]
4. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma.
Nakamura T; Miyabe H; Hyodo M; Sato Y; Hayakawa Y; Harashima H
J Control Release; 2015 Oct; 216():149-57. PubMed ID: 26282097
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11b
Khalifa AM; Nakamura T; Sato Y; Harashima H
Exp Hematol Oncol; 2024 Mar; 13(1):36. PubMed ID: 38553761
[TBL] [Abstract][Full Text] [Related]
6. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice.
Takeda K; Nakayama M; Sakaki M; Hayakawa Y; Imawari M; Ogasawara K; Okumura K; Smyth MJ
J Leukoc Biol; 2011 Oct; 90(4):777-85. PubMed ID: 21712396
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
Dhupkar P; Gordon N; Stewart J; Kleinerman ES
Cancer Med; 2018 Jun; 7(6):2654-2664. PubMed ID: 29733528
[TBL] [Abstract][Full Text] [Related]
11. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
12. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I
Wolf NK; Blaj C; Picton LK; Snyder G; Zhang L; Nicolai CJ; Ndubaku CO; McWhirter SM; Garcia KC; Raulet DH
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2200568119. PubMed ID: 35588144
[TBL] [Abstract][Full Text] [Related]
13. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
[TBL] [Abstract][Full Text] [Related]
14. DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.
Kawai M; Nakamura T; Miura N; Maeta M; Tanaka H; Ueda K; Higashi K; Moribe K; Tange K; Nakai Y; Yoshioka H; Harashima H; Akita H
Nanomedicine; 2018 Nov; 14(8):2587-2597. PubMed ID: 30170077
[TBL] [Abstract][Full Text] [Related]
15. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
16. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer.
Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S
Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511
[No Abstract] [Full Text] [Related]
17. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
18. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
[TBL] [Abstract][Full Text] [Related]
19. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
20. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
